Abstract Increasing occurrence of moderate to severe intrauterine adhesion (IUA) is seriously affecting the quality of human life. The aim of the study was to establish IUA models in nonhuman primates and to explore the dual repair effects of human umbilical cordderived mesenchymal stem cells (huMSCs) loaded on autocrosslinked hyaluronic acid gel (HA-GEL) on endometrial damage and adhesion.
Some good news on the Covid treatment front. Cytokine therapy trials, for mild and moderate symptoms in asymptomatic individuals and early-stage symptomatic Covid-19 infections, will begin from Monday. Though approvals are awaited, doctors are optimistic Starting Monday, HCG Cancer Centre will start conducting cytokine therapy trial on humans, which can treat patients with mild to moderate Covid-19 infection.
21 May 2020 - Austrianova and Cells for Cells have just jointly published a ground breaking, peer reviewed, scientific publication on a novel, cost and time-saving method to generate extra-cellular vesicles (EVs) from encapsulated Mesenchymal Stem Cells (MSCs). These EVs are known to mediate many of the therapeutic effects of stem cells. The authors show that Austrianovas proprietary Cell-in-a-Box encapsulation technology can be used to produce and deliver EVs from encapsulated MSCs, as demonstrated using Cells for Cells proprietary MSCs
The results of a new clinical trial published in the journal STEM CELLS Translational Medicine demonstrate how a topical solution made up of stem cells leads to the regrowth of hair for people with a common type of baldness.1 Unfortunately, there are only a few FDA-approved medications to treat hair loss, and these carry a myriad of associated side effects including a negative impact on sexual functioning.
Coronavirus health scams are rampant, with businesses taking advantage of peoples fears to sell all sorts of unproven products for the prevention and treatment of COVID-19. Some of these snake oil cures are innocuous, such as elderberry juice, but others can be harmful, such as colloidal silver. Among the products with considerable potential for harm are unproven stem cell therapies
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK) today announced it has received authorization from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with BM-Allo.MSC, an allogeneic mesenchymal stem cell (MSC) product derived from human bone marrow
Currently definitive treatment against civid is unavailable while patients are being offered palliative treatment to manage symptoms. Many known therapeutic agents like antivirals (Remdesivir or Hydroxychloroquine) or antiparasitic (Ivermectin) are being evaluated for their efficacy against the disease, although without any comprehensive success
MINNEAPOLIS & EL SEGUNDO, Calif.--(BUSINESS WIRE)--Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, and NantKwest (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer and infectious diseases, today announced an agreement through which Be The Match BioTherapies is providing donor material for a NantKwest Phase 1b clinical trial to address acute respiratory distress syndrome (ARDS), one of the primary causes of COVID-19 deaths. The agreement combines Be The Match BioTherapies ability to provide high-quality cellular source material from the worlds largest registry of volunteer donors with NantKwests capabilities in manufacturing off-the-shelf cell therapies
The recent report on Cell Freezing Media for Cell Therapy market provides an end-to-end assessment of this business sphere and comprises of important data regarding the pivotal parameters such as prevailing market trends, current revenue, market share, industry size, periodic deliverables, and profit estimates over the forecast duration. New latest Growth Report on Cell Freezing Media for Cell Therapy Market Size, Share | Industry Segment by Applications (Human Embryonic Stem Cells, CAR-T Cell Therapy, Neural Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Hematopoietic Stem Cell Transplantation and Other), by Type (With FBS and Without FBS), Regional Outlook, Market Demand, Latest Trends, Industry Growth & Revenue by Manufacturers, Company Profiles & Forecasts to 2025.
The Food and Drug Administration (FDA) has approved a phase 1/2a study evaluating the use of umbilical cord mesenchymal stem cells for the treatment of patients with severe cases of coronavirus disease 2019 (COVID-19). The multicenter, randomized, blinded, placebo-controlled SUCCESS (Systemic Umbilical Cord Cells to Ease Severe Syndrome) study will assess the efficacy and safety of umbilical cord mesenchymal stem cells provided by RESTEM, a cell-based therapeutics company, in hospitalized patients with severe COVID-19 (N=60). RESTEMs cells are grown from umbilical cord tissue through a proprietary process that rapidly replicates millions of doses.
Recent Comments